6
Registered trials
4
Recruiting
5
Unique sponsors
6
Unique IMPs
1
Commercial trials
Drug classes (ATC)
—
ATC code not specified
3
C
Cardiology (ATC C)
1
V
Various (ATC V)
1
J
Anti-infectives (ATC J)
1
B
Haematology (ATC B)
1
Mechanism of action (INN-stem analysis)
Unknown / small molecule
3 substances
Antiviral
2 substances
Receptor fusion protein
1 substance
Phase III:
5
Phase II:
1
Phase III
5 trials-
RecruitingBristol-Myers Squibb Services Unlimited Company CommercialBELATACEPT
-
PendingCHRU De Nancy AcademicIMP not specified
-
RecruitingCHRU De Nancy AcademicEPLERENONE; IOHEXOL
-
RecruitingFundacion Para La Investigacion Biomedica De Cordoba AcademicGANCICLOVIR; VALGANCICLOVIR HYDROCHLORIDE
-
PendingUniversity Hospital Of Canary Islands AcademicACETYLCYSTEINE, GLYCINE, L-LYSINE ACETATE, L-TRYPTOPHAN, GLYCYL-TYROSINE, L-ARGININE, L-HISTIDINE, L-ISOLEUCINE, L-LEUCINE, L-METHIONINE, L-PROLINE, L-SERINE, L-THREONINE, L-TYROSINE, L-VALINE, L-PHENYLALANINE, L-ALANINE
Phase II
1 trial-
RecruitingCentre Hospitalier Universitaire Rouen AcademicIMP not specified
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| CHRU De Nancy | Academic | 2 | Phase III | 1 |
| Bristol-Myers Squibb Services Unlimited Company | Commercial | 1 | Phase III | 1 |
| Centre Hospitalier Universitaire Rouen | Academic | 1 | Phase II | 1 |
| Fundacion Para La Investigacion Biomedica De Cordoba | Academic | 1 | Phase III | 1 |
| University Hospital Of Canary Islands | Academic | 1 | Phase III | 0 |
New trials by year
2021
1
2024
1
2025
2